​

Faeth Therapeutics (FTH) Stock Forecast, Price Target & Predictions

OverviewFinancialsChart

FTH Stock Forecast

Faeth Therapeutics (FTH) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $58.50, with a high of $70.00 and a low of $50.00. This represents a 449.30% increase from the last price of $10.65.

$5 $18 $31 $44 $57 $70 High: $70 Avg: $58.5 Low: $50 Last Closed Price: $10.65

FTH Stock Rating

Faeth Therapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

FTH Price Target Upside V Benchmarks

TypeNameUpside
StockFaeth Therapeutics449.30%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-38
Avg Price Target-$61.67$58.50
Last Closing Price$10.65$10.65$10.65
Upside/Downside-479.06%449.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 26312---15
Oct, 26311---14
Sep, 2639---12
Aug, 2628---10
Jul, 26-7---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 15, 2026Brad CaninoGuggenheim$70.00$35.3797.91%557.28%
Sep 14, 2026UBS$59.00$39.2450.36%453.99%
Aug 21, 2026Gil BlumNeedham$56.00$32.1074.45%425.82%
Jul 31, 2026Sean McCutcheonRaymond James$56.00$28.8294.31%425.82%
Jul 27, 2026Oppenheimer$60.00$29.24105.20%463.38%
Jun 25, 2026Jack AllenRobert W. Baird$57.00$24.67131.05%435.21%
Jun 22, 2026H.C. Wainwright$60.00$17.82236.70%463.38%
May 28, 2026Christopher LiuLoop Capital Markets$50.00$16.65200.30%369.48%
May 13, 2024Sudan LoganathanStephens$5.00$1.57218.47%-53.05%
Dec 13, 2022Citigroup$6.00$1.74244.83%-43.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 10, 2026H.C. WainwrightBuyBuyhold
Oct 27, 2026Cantor FitzgeraldOverweightOverweighthold
Oct 16, 2026William BlairOutperforminitialise
Oct 07, 2026Cantor FitzgeraldOverweightOverweighthold
Sep 15, 2026GuggenheimBuyinitialise
Sep 09, 2026Cowen & Co.Buyinitialise
Aug 21, 2026NeedhamBuyinitialise
Jul 31, 2026Raymond JamesOutperforminitialise
Jul 27, 2026OppenheimerOutperformOutperforminitialise
Jul 20, 2026CitigroupBuyOutperforminitialise

Financial Forecast

EPS Forecast

$-150 $-120 $-90 $-60 $-30 $0 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29 Dec 30
Dec 25Dec 26Dec 27Dec 28Dec 29Dec 30
Reported$-16.72-----
Avg Forecast$-18.17$-132.38$-6.53$-5.75$-5.26$-4.96
High Forecast$-18.17$-132.38$-6.53$-2.70$-5.26$-4.96
Low Forecast$-18.17$-132.38$-6.53$-8.80$-5.26$-4.96
Surprise %-7.98%-----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 25 Dec 26 Dec 27 Dec 28 Dec 29 Dec 30
Dec 25Dec 26Dec 27Dec 28Dec 29Dec 30
Reported------
Avg Forecast---$16.83M$74.20M$137.15M
High Forecast---$16.83M$74.20M$137.15M
Low Forecast---$16.83M$74.20M$137.15M
Surprise %------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29 Dec 30
Dec 25Dec 26Dec 27Dec 28Dec 29Dec 30
Reported$-21.09M-----
Avg Forecast$-22.91M$-166.91M$-8.23M$-7.25M$-6.63M$-6.26M
High Forecast$-22.91M$-166.91M$-8.23M$-3.40M$-6.63M$-6.26M
Low Forecast$-22.91M$-166.91M$-8.23M$-11.09M$-6.63M$-6.26M
Surprise %-7.96%-----

FTH Forecast FAQ

Is Faeth Therapeutics stock a buy?

Faeth Therapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Faeth Therapeutics is a favorable investment for most analysts.

What is Faeth Therapeutics's price target?

Faeth Therapeutics's price target, set by 6 Wall Street analysts, averages $58.5 over the next 12 months. The price target range spans from $50 at the low end to $70 at the high end, suggesting a potential 449.30% change from the previous closing price of $10.65.

How does Faeth Therapeutics stock forecast compare to its benchmarks?

Faeth Therapeutics's stock forecast shows a 449.30% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Faeth Therapeutics over the past three months?

  • November 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 21.43% Strong Buy, 78.57% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Faeth Therapeutics’s EPS forecast?

Faeth Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-132, marking a 691.75% increase from the reported $-16.72 in 2025. Estimates for the following years are $-6.53 in 2027, $-5.75 in 2028, $-5.26 in 2029, and $-4.96 in 2030.

What is Faeth Therapeutics’s revenue forecast?

Faeth Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, followed by $16.83M for 2028, $74.2M for 2029, and $137.15M for 2030.

What is Faeth Therapeutics’s net income forecast?

Faeth Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-167M, representing an 691.58% increase from the reported $-21.085M in 2025. Projections indicate $-8.231M in 2027, $-7.246M in 2028, $-6.632M in 2029, and $-6.257M in 2030.